Literature DB >> 2983132

Development and early natural history of HTLV-III antibodies in persons with hemophilia.

M E Eyster, J J Goedert, M G Sarngadharan, S H Weiss, R C Gallo, W A Blattner.   

Abstract

Antibodies to human T-cell lymphotropic virus type III (HTLV-III) were first detected in 1979 in serum samples from 30 known seropositive patients with hemophilia, over half of whom seroconverted in 1981-1982. Lymphadenopathy was present in 70% who were seropositive more than three years, compared with 10% who were seropositive three years or less. T-helper cell counts were low (307 +/- 64 cells/cu mm) in the early seroconverters, and normal in the late seroconverters. T-suppressor cell counts were not related to the year of seroconversion. The long latency period after seroconversion suggests an ongoing indolent process, rather than an acute infection. It remains to be determined whether this is an aberrant part of the immune response initiated by HTLV-III antigens or the result of a chronic active HTLV-III infection.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2983132

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  16 in total

Review 1.  The natural history of human T lymphotropic virus-III infection: the cause of AIDS.

Authors:  M Melbye
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-04

2.  Age and human immunodeficiency virus infection in persons with hemophilia in California.

Authors:  R C Holman; E D Gomperts; J M Jason; C F Abildgaard; M T Zelasky; B L Evatt
Journal:  Am J Public Health       Date:  1990-08       Impact factor: 9.308

3.  Markers of HTLV-III in patients with end stage renal failure treated by haemodialysis.

Authors:  M Goldman; C Liesnard; J L Vanherweghem; N Dolle; C Toussaint; S Sprecher; J Cogniaux; L Thiry
Journal:  Br Med J (Clin Res Ed)       Date:  1986-07-19

Review 4.  Progressive change in lymphocyte distribution and degree of hypergammaglobulinemia with age in children with hemophilia.

Authors:  B T Shannon; J Roach; M Cheek-Luten; C Orosz; F B Ruymann
Journal:  J Clin Immunol       Date:  1986-03       Impact factor: 8.317

5.  Altered immunity in hemophilia correlates with the presence of antibody to human T-cell lymphotropic virus type III (HTLV-III).

Authors:  C R Horsburgh; K C Davis; U Hasiba; S H Weiss; J J Goedert; P Sarin; C H Kirkpatrick
Journal:  J Clin Immunol       Date:  1986-01       Impact factor: 8.317

6.  Human immunodeficiency virus (HIV) infection in haemophiliacs: long-term prognostic significance of the HIV serologic pattern.

Authors:  K Raska; H C Kim; K Raska; E Martin; J Raskova; P Saidi
Journal:  Clin Exp Immunol       Date:  1989-07       Impact factor: 4.330

7.  Construction and use of a replication-competent human immunodeficiency virus (HIV-1) that expresses the chloramphenicol acetyltransferase enzyme.

Authors:  E F Terwilliger; B Godin; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

8.  Epidemiological aspects of HTLV-III infection in Italy.

Authors:  P Rossi; M Carbonari; R Bonomo; M Galli; P E Manconi; B Scarpati; G Scano; C Gaetano; B Ensoli; F Aiuti
Journal:  Eur J Epidemiol       Date:  1985-12       Impact factor: 8.082

9.  The Vancouver Lymphadenopathy-AIDS Study: 5. Antecedent behavioural, clinical and laboratory findings in patients with AIDS and HIV-seropositive controls.

Authors:  W J Boyko; M T Schechter; K J Craib; P Constance; R Nitz; S Fay; A McLeod; M O'Shaughnessy
Journal:  CMAJ       Date:  1986-10-15       Impact factor: 8.262

10.  Phorbol ester enhances human immunodeficiency virus-promoted gene expression and acts on a repeated 10-base-pair functional enhancer element.

Authors:  J D Kaufman; G Valandra; G Roderiquez; G Bushar; C Giri; M A Norcross
Journal:  Mol Cell Biol       Date:  1987-10       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.